RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 1
PRIONS M...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 2
 Other ...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 3
II. REPO...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 4
bodies i...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 5
Global M...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 6
BSE Post...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 7
III. MAR...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 8
Exhibit ...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 9
IV. PROD...
RITMIR019: Prions – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 10
The cop...
Upcoming SlideShare
Loading in...5
×

Prions and Viroids, Prions research report

253

Published on

Prions Market Research report gives an insight into the global market for Prion Deactivation technologies, Post Mort em Testing for BSE and Prion Reduction Filters. The Prion related products include BSE detection test Kits, Deactivation/Inactivation technologies, Reagents and Services. The study includes estimations and predictions for the global BSE Post Mortem Testing Market. The market is also analyzed by geographic regions encompassing North America, Europe, Japan and Rest of World. Business profiles of 25 major companies are discussed in the report. The report serves as a complete guide to global Prion Detection, Reduction and Inactivation Market covering more than 120 companies that are engaged in research for development of antemortem BSE and CJD test kits, development and supply of BSE Test kits and development of prion Reduction Filters. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
253
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Prions and Viroids, Prions research report

  1. 1. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 1 PRIONS MARKET SIZE Scope of the Study Prions report gives an insight into the market for Prion Deactivation technologies, Post Mortem Testing for BSE and Prion Reduction Filters. The Prion related products include BSE detection test Kits, Deactivation /Inactivation technologies, Reagents and Services. The study includes estimates and projections for the global BSE Post Mortem Testing Market. Projections and estimates are also illustrated by geographic region encompassing North America, Europe, Japan and Rest of World. Business profiles of 24 major companies are discussed in the report. The report serves as a guide to global Prion Detection, Reduction and Inactivation Market as it covers more than 120 companies that are engaged in research for development of antemortem BSE and CJD test kits, development and supply of BSE Test kits and development of prion Reduction Filters. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report. Prions report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in-  Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets Analytics and data presented in this report pertain to several parameters such as -  Global And Regional Market Sizes, Market Shares, Market Trends  Product (Global And Regional) Market Sizes, Market Shares, Market Trends  Technology Trends  Corporate Intelligence  Key Companies By Sales, Brands, Products  Consumer Behavioral Patterns
  2. 2. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 2  Other Strategic Business Affecting Data Research Methodology RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines - global market analysis, regional market analysis, product segmentation, global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the market size for the future. This report is uniquely researched and the methodology includes:  Need and Scope of Study  Product Definitions  Segmental Analysis  Regional Analysis  Exclusive Data Analytics  Corporate Intelligence  Feedback Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings. Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies.
  3. 3. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 3 II. REPORT SYNOPSIS Prions are considered unique as they replicate without the presence of nucleic acids. These are observed to replicate by modifying neighboring prions to conform to the required shape. After the completion of the protein reconfirmation the modified or mutated prion becomes infective. In 1982, Stanley B. Prusiner, a professor at University of California, San Francisco coined the word “Prions” for referring to proteinaceous infectious particles. These particles have no other content except proteins. Therefore, they are identified as a separate category of particles like virions, which term refers to virus containing infectious materials. The reason that prions are gaining importance is because they cause certain neurodegenerative diseases in animals and humans, which are incurable as of date. Creutzfeldt-Jakob disease in humans and Bovine spongiform encephalopathy (mad cow disease) are two such examples. The infected person or animal dies within months or even weeks after the symptoms start surfacing. Physicist J.S. Griffith and radiation biologist Tikvah Alper were the first to suggest that infectious particles comprised only of proteins cause some of the transmissible spongiform encephalopathies. This disease was detected in the early 1970’s and the researcher involved in the extensive research of this disease Mr. Carleton Gajdusek was awarded Nobel Prize for Medicine in 1976. Transmissible spongiform encephalopathy [TSE] is a neurodegenerative disease caused by an altered form of a cellular prion protein [PrPC]. The disease is expressed as bovine spongiform encephalopathy [BSE] in cattle, scrapie in sheep, chronic wasting disease [CWD] in elk and deer, and Creutzfeldt-Jakob disease [CJD] in humans. The scientists across the world are anxiously waiting to unearth a link between the disease scrapie, which is commonly found in the goats and sheep with that of other diseases like bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD). This is expected to bring about a revolution in the field of both agriculture and pharmaceutical developments. The very information pertaining to this research created a widespread impact on the pharmaceutical industries and its development can be witnessed in proportion. The disease is caused by mutated prions, and is not similar to other diseases that affect human beings and domestic animals. The main responsibility to control this disease is vested with the pharmaceutical industry and it is influenced in several ways. The following steps are to be ensured to restrict the disease progression:  The main aim is to restrict the disease in the geographical area where it is found without further expansion to other areas and the ultimate aim would be eliminate the disease completely.  Further, it is also mandatory to evaluate continual risk assessment with respect to the product imported.  The programmes that promote the use of TSE free animals are to be widely encouraged. Majority of the diagnostic antibodies utilized in the bio manufacturing process across the world are extracted from goats or sheep. The research carried out in this area indicates that the presence of scrapie in blood products cannot be ignored. The serum, plasma of these animals needs to be subjected to intensive scrutiny before they are introduced into the diagnostic marketplace. The international regulatory
  4. 4. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 4 bodies involved in the scrutiny of such products recommend the use of TSE-free animals for diagnostics and pharmaceutical practices. Exhibit 1. Mammalian Agents of Spongiform Encephalopathies, ICTVdb Code, Disease Name, Natural Host, Prion Name and PrP Iso Form ICTVdb Code Disease Name Natural Host Prion Name PrP Iso Form 90.001.0.01.001. Scrapie Sheep and goats Scrapie prion OvPrPSc 90.001.0.01.002. Transmissible mink encephalopathy (TME) Mink TME prion MkPrPSc 90.001.0.01.003. Chronic wasting disease (CWD) Elk, White-tailed deer, Mule Deer and Red Deer CWD prion MDePrPSc 90.001.0.01.004. Bovine spongiform encephalopathy (BSE) Cattle BSE prion BovPrPSc 90.001.0.01.005. Feline spongiform encephalopathy (FSE) Cats FSE prion FePrPSc 90.001.0.01.006. Exotic ungulate encephalopathy (EUE) Nyala and greater kudu EUE prion NyaPrPSc 90.001.0.01.007. Kuru Humans Kuru prion HuPrPSc 90.001.0.01.008. Creutzfeldt-Jakob disease (CJD) Humans CJD prion HuPrPSc (New) Variant Creutzfeldt-Jakob disease (vCJD, nvCJD) Humans vCJD prion HuPrPSc 90.001.0.01.009. Gerstmann-Sträussler-Scheinker syndrome (GSS) Humans GSS prion HuPrPSc 90.001.0.01.010. Fatal familial insomnia (FFI) Humans FFI prion HuPrPSc © RIT, 2013 General Definitions Genetic Disorder: The pathological condition caused by a chromosomal aberration or by absence of gene of a defective gene. Sporadic Disease: Disease occurring at irregular intervals; having no order or pattern in time. Iatrogenic Disease: An iatrogenic disease may be inadvertently caused by a physician or surgeon or by a medical or surgical treatment or a diagnostic procedure.
  5. 5. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 5 Global Market Analysis Deactivation Technologies Global Prion Deactivation Technologies market is projected to reach about US$ XX.XX billion by 2020 from an estimated US$ XX.XX million in 2012, growing at a compounded annual growth rate (CAGR) of XX.XX % during the analysis period of 2005-2020. Exhibit 2. Prion Deactivation Technologies - Global Value Market Estimations & Predictions (2005-2020) in US$ Million Year Value 2005 XX.XX 2006 XX.XX 2007 XX.XX 2008 XX.XX 2009 XX.XX 2010 XX.XX 2011 XX.XX 2012 XX.XX 2013 XX.XX 2014 XX.XX 2015 XX.XX 2016 XX.XX 2017 XX.XX 2018 XX.XX 2019 XX.XX 2020 XX.XX CAGR% XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Million
  6. 6. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 6 BSE Post Morterm Testing Global BSE Post Mortem Testing market is projected to reach about US$ XX.XX million by 2020 from an estimated US$ XX.XX million in 2012, growing at compounded annual growth rate (CAGR) of XX.XX % during the analysis period of 2005-2020. Exhibit 3. BSE Post Mortem Testing - Global Value Market Estimations & Predictions (2005-2020) in US$ Million Year Value 2005 XX.XX 2006 XX.XX 2007 XX.XX 2008 XX.XX 2009 XX.XX 2010 XX.XX 2011 XX.XX 2012 XX.XX 2013 XX.XX 2014 XX.XX 2015 XX.XX 2016 XX.XX 2017 XX.XX 2018 XX.XX 2019 XX.XX 2020 XX.XX CAGR% XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Million
  7. 7. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 7 III. MARKET DYNAMICS Market Overview The scientists across the world are anxiously waiting to unearth a link between the disease scrapie, which is commonly found in the goats and sheep with that of other diseases like bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD). This is expected to bring about a revolution in the field of both agriculture and pharmaceutical developments. The serum, plasma of animals used for preparing antibodies needs to be subjected to intensive scrutiny before they are introduced into the diagnostic marketplace. The international regulatory bodies involved in the scrutiny of such products recommends the use of TSE-free animals for diagnostics and pharmaceutical practices thus increasing market for Prion Reduction and Deactivation technologies. European Union has imposed very stringent measures for controlling TSE infections in domestic animals. Slaughterhouses in EU are required to test for BSE even the healthy cattle that are 30 years or more of age. From the cattle that die on the farm, those that are 24 months or more of age have to be tested for BSE. Out of the cattle being sent for rendering, those that are 24 months and above of age, are to be tested for presence of BSE infection before rendering. Apart from these, any cattle, which displays any physical symptom of BSE, has to be tested, irrespective of the age thus increasing the market for BSE testing in Europe. Only 10% of cows are tested for BSE in the US. The new US policy is a sharp contrast to the measures taken by countries such as Japan, where 100 percent of cows are tested for BSE infection at the time of slaughtering, to ensure that the meat is safe for human consumption. Japan insists that all the cattle be tested at the time of slaughter. Prion Reduction Filters – Global Market Analysis Global market for Prion Reduction Filters is projected to reach about US$ XX.XX million by 2020 from an estimated US$ XX.XX million in 2012, growing at a Compounded Annual Growth Rate (CAGR) of XX.XX % during the analysis period, 2005-2020. Europe was estimated as the largest market for Prion Reduction Filters in 2012 with a share of XX.XX % valued at US$ XX.XX million and is projected to reach US$ XX.XX million by 2020 to retain its position with a share of XX.XX %. North America is projected to be the second largest market with a market share of XX.XX % in 2020. Japanese market for Prion Reduction Filters is valued at US$ XX.XX million with a market share of XX.XX % in 2010 and is projected to reach US$ XX.XX million by 2020.
  8. 8. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 8 Exhibit 4. Prion Reduction Filters - Global Value Market Estimations & Predictions (2005-2020) by Geographic Regions for Europe, North America, Japan and Rest of World in US$ Million Year /Region Europe North America Japan Rest of World Total 2005 XX.XX XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Million Europe North America Japan Rest of World
  9. 9. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 9 IV. PRODUCT/TECHNOLOGY RESEARCH Exhibit 5. Preventive Measures against the Introduction and Spread of BSE in the EU Year Events April 9, 1990 Animals to be slaughtered are required to be inspected by veterinarians to prevent entry into food and feed chains July, 1994 (MBM) Mammalian Bone meal was banned from feeding to sheep, goat and cattle. January 1, 1995 For treatment of animal waste processing standards are implemented. April 1, 1997 For the production of MBM from animal waste pressure cooking regulations are implemented(133 °C/3 bars/20 minutes) October 2000 EU mandated SRMs are to be removed from goats, cattle, sheep from animal and human food chains through out Europe. January 2001 Use of animal protein for the production of feed for animals is banned. March 2001 Vertebral column, intestine of bovines are included in the list of SRM July 2001 Animals with high probability of receiving the same infected feed as the BSE cases are culled. Due to potential of maternal transmission latest born offspring of the female BSE cases are culled. *(SRMs) includes Spinal Cord, Brain, Eyes, Tonsils, Parts of Intestine © RIT, 2013 About RI Technologies RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development. Research – As Good as the Methodology is!  Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets © COPYRIGHT
  10. 10. RITMIR019: Prions – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 10 The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company. DISCLAIMER RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.

×